[go: up one dir, main page]

WO2024026500A3 - Inhibiteurs de pde11a4 et leurs méthodes d'utilisation - Google Patents

Inhibiteurs de pde11a4 et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2024026500A3
WO2024026500A3 PCT/US2023/071289 US2023071289W WO2024026500A3 WO 2024026500 A3 WO2024026500 A3 WO 2024026500A3 US 2023071289 W US2023071289 W US 2023071289W WO 2024026500 A3 WO2024026500 A3 WO 2024026500A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde11a4
inhibitors
methods
same
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/071289
Other languages
English (en)
Other versions
WO2024026500A2 (fr
Inventor
Shams ul MAHMOOD
Michele Patrice KELLY
David ROTELLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MONTCLAIR STATE UNIVERSITY
University of Maryland Baltimore
MONTCLAIR STATE UNIV
University of Maryland College Park
Original Assignee
MONTCLAIR STATE UNIVERSITY
University of Maryland Baltimore
MONTCLAIR STATE UNIV
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MONTCLAIR STATE UNIVERSITY, University of Maryland Baltimore, MONTCLAIR STATE UNIV, University of Maryland College Park filed Critical MONTCLAIR STATE UNIVERSITY
Priority to EP23847619.6A priority Critical patent/EP4561567A2/fr
Publication of WO2024026500A2 publication Critical patent/WO2024026500A2/fr
Publication of WO2024026500A3 publication Critical patent/WO2024026500A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des inhibiteurs de PDE11A4, et des méthodes d'utilisation de ceux-ci pour traiter ou prévenir des maladies ou un trouble associé à un déclin cognitif.
PCT/US2023/071289 2022-07-28 2023-07-28 Inhibiteurs de pde11a4 et leurs méthodes d'utilisation Ceased WO2024026500A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23847619.6A EP4561567A2 (fr) 2022-07-28 2023-07-28 Inhibiteurs de pde11a4 et leurs méthodes d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263393187P 2022-07-28 2022-07-28
US63/393,187 2022-07-28
US202263370546P 2022-08-05 2022-08-05
US63/370,546 2022-08-05

Publications (2)

Publication Number Publication Date
WO2024026500A2 WO2024026500A2 (fr) 2024-02-01
WO2024026500A3 true WO2024026500A3 (fr) 2024-03-07

Family

ID=89707415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071289 Ceased WO2024026500A2 (fr) 2022-07-28 2023-07-28 Inhibiteurs de pde11a4 et leurs méthodes d'utilisation

Country Status (2)

Country Link
EP (1) EP4561567A2 (fr)
WO (1) WO2024026500A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053931A1 (en) * 2001-06-21 2004-03-18 Cox Paul J. Azaindoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053931A1 (en) * 2001-06-21 2004-03-18 Cox Paul J. Azaindoles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE - PubChem ANONYMOUS : "AKOS034445369 ", XP093148248, retrieved from NCBI *
DATABASE PubChem NCBI; ANONYMOUS : "SID-144331418", XP093148243 *

Also Published As

Publication number Publication date
EP4561567A2 (fr) 2025-06-04
WO2024026500A2 (fr) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2021011488A (es) Compuestos y usos de estos.
WO2020252229A3 (fr) Inhibiteurs de sarm1
WO2024040109A3 (fr) Inhibiteurs de kras
WO2021229507A3 (fr) Méthodes, thérapies et utilisations pour le traitement du cancer
WO2022109396A8 (fr) Composés et leurs utilisations
WO2005044093A3 (fr) Compositions de delta-9-thc et methodes de traitement de symptomes lies la sclerose en plaques
WO2020154571A8 (fr) Composés et leurs utilisations
WO2023122260A3 (fr) Inhibiteurs du sars-cov-2
EP4331683A3 (fr) Procédés et compositions pour le traitement de la chute des cheveux
WO2021195470A3 (fr) Identification et utilisation de composés dans le traitement ou la prévention du coronavirus 2 responsable du syndrome respiratoire aigu sévère
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2023240199A3 (fr) Traitement de l'hémophilie avec le fitusiran
WO2024026500A3 (fr) Inhibiteurs de pde11a4 et leurs méthodes d'utilisation
WO2020047144A3 (fr) Formulations ophtalmiques, leur procédé de préparation et leur procédé d'administration
CR20240023A (es) Compuestos de sulfonimidamida y usos de los mismos
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2021247916A8 (fr) Composés d'azétidine et de spiroazétidine et leurs utilisations
WO2024191937A3 (fr) Compositions et méthodes de traitement, d'amélioration et/ou de prévention de maladies et/ou de troubles
MX2024012789A (es) Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa)
WO2025057134A3 (fr) Agoniste de glp-1r et méthode thérapeutique associée
EP4378532A3 (fr) Composés et procédés pour traiter des pathologies fibrotiques
WO2021102359A3 (fr) Inhibiteurs de taspase1 et leurs utilisations
WO2020185651A3 (fr) Compositions et méthodes de traitement de la maladie de huntington
EP4603145A3 (fr) Traitement de la douleur associée à la sensibilisation centrale
EP4337324A4 (fr) Méthodes pour l'identification et le traitement de formes sévères de covid-19

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23847619

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2023847619

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023847619

Country of ref document: EP

Effective date: 20250228

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23847619

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023847619

Country of ref document: EP